Posted 11th December 2017 by Jane Williams
It is that time of the year to celebrate the most significant breakthroughs and accomplishments in the field of digital pathology. 2017 has been an exciting year with Philips receiving FDA approval to market their IntelliSite Pathology Solution for primary diagnostic use in the US.
Posted 22nd September 2017 by Jane Williams
With the recent shift in the industry as the result of this decision, a common question is “What lies in store for digital pathology system manufacturers in the wake of the FDA granting Philips’ de novo classification request for its IntelliSite device?”
Posted 4th September 2017 by Jane Williams
For the past decade-plus, the digital pathology industry, pathologists and regulators have had conferences, meetings, and association and society gatherings to figure out how to ensure safe and effective use of whole slide imaging. Early meetings focused on pixels and colours. Subsequent discussions were about study designs and clinical validation.
Posted 19th June 2017 by Jane Williams
Anyone reading this would be familiar that in April the FDA determined after an extensive clinical trial that a whole slide imaging system presents no greater risk to patient care than an optical microscope. In a purely scientific study design, there is a null hypothesis that states “there is no significant difference between…” and then investigators try to prove or disprove that hypothesis.
Posted 13th April 2017 by Jane Williams
It has just been announced that the FDA has taken the long awaited step in the move towards wider use of digital pathology. Philips has received permission to market their IntelliSite Pathology Solution for primary diagnostic use in the United States. Is this the first step towards full acceptance of this technology as a front line diagnostic tool?